Correlation Between Plasma- and Endothelial DPP-4 Activity
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The investigators want to estimate both the endothelial and the plasma activity of dipeptidyl
peptidase 4 during different doses of sitagliptin in healthy subjects and patients with type
2 diabetes. Furthermore, the investigators want to investigate whether the current clinical
dose of 100 mg of sitagliptin is sufficient to inhibit both the plasma and the endothelial
activity of the enzyme dipeptidyl peptidase 4.